Literature DB >> 22710756

The role of the immune system in the generation of neuropathic pain.

Margarita Calvo1, John M Dawes, David L H Bennett.   

Abstract

Persistent pain is a sequela of several neurological conditions with a primary immune basis, such as Guillain-Barré syndrome and multiple sclerosis. Additionally, diverse forms of injury to the peripheral or the central nervous systems--whether traumatic, metabolic, or toxic--result in substantial recruitment and activation of immune cells. This response involves the innate immune system, but evidence also exists of T-lymphocyte recruitment, and in some patient cohorts antibodies to neuronal antigens have been reported. Mediators released by immune cells, such as cytokines, sensitise nociceptive signalling in the peripheral and central nervous systems. Preclinical data suggest an immune pathogenesis of neuropathic pain, but clinical evidence of a central role of the immune system is less clear. An important challenge for the future is to establish to what extent this immune response initiates or maintains neuropathic pain in patients and thus whether it is amenable to therapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22710756     DOI: 10.1016/S1474-4422(12)70134-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  154 in total

Review 1.  Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.

Authors:  Christopher Eccleston; Tess E Cooper; Emma Fisher; Brian Anderson; Nick Mr Wilkinson
Journal:  Cochrane Database Syst Rev       Date:  2017-08-02

Review 2.  Topical capsaicin (high concentration) for chronic neuropathic pain in adults.

Authors:  Sheena Derry; Andrew Sc Rice; Peter Cole; Toni Tan; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

Review 3.  Tramadol for neuropathic pain in adults.

Authors:  Rudolf Martin Duehmke; Sheena Derry; Philip J Wiffen; Rae F Bell; Dominic Aldington; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-06-15

Review 4.  Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.

Authors:  Stephen D Skaper; Laura Facci; Mariella Fusco; Maria Federica Della Valle; Morena Zusso; Barbara Costa; Pietro Giusti
Journal:  Inflammopharmacology       Date:  2013-11-01       Impact factor: 4.473

Review 5.  Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents.

Authors:  Tess E Cooper; Lauren C Heathcote; Brian Anderson; Marie-Claude Grégoire; Gustaf Ljungman; Christopher Eccleston
Journal:  Cochrane Database Syst Rev       Date:  2017-07-24

Review 6.  Crosstalk between the nociceptive and immune systems in host defence and disease.

Authors:  Stephen B McMahon; Federica La Russa; David L H Bennett
Journal:  Nat Rev Neurosci       Date:  2015-07       Impact factor: 34.870

Review 7.  Methadone for neuropathic pain in adults.

Authors:  Ewan D McNicol; McKenzie C Ferguson; Roman Schumann
Journal:  Cochrane Database Syst Rev       Date:  2017-05-17

8.  Gut Microbiota Dysbiosis Enhances Migraine-Like Pain Via TNFα Upregulation.

Authors:  Yuanyuan Tang; Sufang Liu; Hui Shu; Lora Yanagisawa; Feng Tao
Journal:  Mol Neurobiol       Date:  2019-08-04       Impact factor: 5.590

Review 9.  Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain.

Authors:  Paola Sacerdote; Silvia Franchi; Sarah Moretti; Mara Castelli; Patrizia Procacci; Valerio Magnaghi; Alberto E Panerai
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-16       Impact factor: 4.147

Review 10.  Oxycodone for neuropathic pain in adults.

Authors:  Helen Gaskell; Sheena Derry; Cathy Stannard; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.